MSD

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

Verona shareholders back $10bn MSD takeover

MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK firm's shareholders.

News

MSD's $349m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

News

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

News